GSK’s drug Blenrep, previously pulled from the market, has shown promising results in a Phase 3 study for treating multiple myeloma earlier in the treatment process. The drug has demonstrated longer progression-free survival and overall survival rates compared to standard regimens. Blenrep targets BCMA, a protein on multiple myeloma cells, and has the potential to become a new standard of care for this type of blood cancer. Despite previous setbacks, GSK is hopeful that Blenrep could be a significant player in the multiple myeloma market, offering a more accessible treatment option for patients.
Source link
GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH
